頭頸部癌に対するMTX-5FU-CBDCA療法の経験  [in Japanese] Combined MTX-5FU-CBDCA for the Treatment of Head and Neck Cancer  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

Combination chemotherapy including 5FU and carboplatin (CBDCA) with methotrexate (MTX) and leucovorin (LV) as biochemical modulation was performed on patients with head and neck cancer. A total of 32 patients were treated in the order of MTX, continuous 5FU infusion and LV injection, CBDCA. 24 of the 32 patients were concurrently treated with radiation therapy. Treatment-associated toxicity was significant, including mucositis, myelosuppression and body weight losses, but they were within acceptable limits. The 5-year survival rates calculated using Kaplan-Meyer methods were 41.3%.

Journal

  • Practica Oto-Rhino-Laryngologica

    Practica Oto-Rhino-Laryngologica 95(1), 81-85, 2002-01-01

    The Society of Practical Otolaryngology

References:  21

Cited by:  2

Codes

  • NII Article ID (NAID)
    10008098721
  • NII NACSIS-CAT ID (NCID)
    AN00107089
  • Text Lang
    JPN
  • Article Type
    Journal Article
  • ISSN
    00326313
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top